5 Key Takeaways

• 1

  Starting SGLT2 inhibitors in older adults on RAAS inhibitors reduced hyperkalemia cases and treatment interruptions.

• 2

  The study involved over 39,000 adults aged 66 and older with diabetes, heart failure, or chronic kidney disease.

• 3

  SGLT2i users had a lower incidence of hyperkalemia at 79 events per 1,000 person-years compared to 90 in nonusers.

• 4

  Discontinuation of RAAS therapy was lower in SGLT2i users at 36% versus 45% in nonusers.

• 5

  The association between SGLT2i use and reduced hyperkalemia risk was consistent across most clinical subgroups.